There have been no large-scale studies on humans, and its role as a clinical therapy is considered scientifically controversial
No serious acromegaly, hypoglycemia, or excessive IGF1 elevations reported at recommended dosages (builtin negative feedback prevents overshooting)
National Library of Medicine Primary regulatory Jul 1, 2026 accessed Jul 1, 2026 ClinicalTrials.gov registry search for AOD-9604 clinical trials, including the Phase 2 obesity program by Metabolic Pharmaceuticals that failed to meet primary weight loss endpoints
The HCG Institute is a patient management platform that partners with independent licensed physician networks to deliver medical services through our infrastructure.This content is educational and is not considered medical advice
Your provider will recommend the right form during your consultation
Patients should maintain adequate hydration and monitor their symptoms